This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
Feb. 29, 2012 /PRNewswire/ -- AMRI (NASDAQ: AMRI) announced today that
Tom McGrath has joined the company as Director, Quality for Aseptic Services at AMRI's
Burlington, Mass. site, reporting to
Junan Guo, Ph.D., Senior Director, Pharmaceutical and Quality Services. Mr. McGrath's more than 15 years of quality systems and quality control experience in the pharmaceutical industry will strengthen AMRI's capabilities in this technically complex area. This appointment further demonstrates AMRI's commitment to providing industry leading aseptic services with uncompromising quality to the company's growing client base.
Mr. McGrath brings more than 15 years of experience in the pharmaceutical industry where he held leadership positions overseeing quality control with multiple biopharmaceutical companies including his most recent role as Quality Control Director at AMAG Pharmaceuticals Inc. His strong technical background and quality management experience will strengthen AMRI's capabilities in the aseptic arena.
Burlington, Mass. facility offers clients innovative aseptic formulation and filling services for pre-clinical through small-volume, commercial-scale production of liquid-filled parenterals, biologics and medical devices in vials, syringes and other custom containers.
"Tom brings extensive knowledge and experience in quality systems enabling product development and commercialization," said
Steven R. Hagen, Ph.D.,
Vice President, Pharmaceutical Development and Manufacturing, AMRI. "With the established quality systems at AMRI Burlington, Tom's leadership will further ensure our objective of providing industry leading quality standards and product performance for our customers."
AMRI is also pleased to announce that
Chris Phillips has been appointed to the role of Senior Director of Operations at the
Burlington site. Working together with Mr. McGrath, Mr. Phillips will continue to focus on insuring that customer projects at AMRI Burlington are managed to completion in accordance with the high standards set by the FDA for the aseptic fill and finish industry.
Albany Molecular Research, Inc. (AMRI) is a global contract research and manufacturing organization with more than twenty years experience providing customers fully integrated drug discovery, development, and manufacturing services. AMRI supplies a broad range of services and technologies that support the discovery and development of pharmaceutical products and the manufacturing of API and drug product for existing and experimental new drugs. With locations in
the United States,
Asia, AMRI maintains geographic proximity and flexible cost models. AMRI has also historically leveraged its drug-discovery expertise to execute on several internal drug discovery programs, which have progressed to the development candidate stage and in some cases into Phase I clinical development. AMRI has successfully partnered certain programs and is actively seeking to out-license its remaining programs to strategic partners for further development.